Testing How Your Body Absorbs a New Tablet Medicine
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests how a new tablet medicine (HRS-2189) moves through your body and how well it's absorbed. Healthy volunteers take the tablet, and researchers measure drug levels in your blood over time to understand if the tablet works as designed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old
- You must weigh at least 45 kg (99 lbs) if female or 50 kg (110 lbs) if male, with a healthy BMI (19–26)
- You cannot have had major surgery in the past year or any surgery in the past month
- You must not smoke (or have smoked 5+ cigarettes daily in the past 3 months) or drink heavily (14+ units of alcohol per week)
- You must have no serious medical conditions affecting your heart, hormones, nerves, stomach, lungs, kidneys, blood, or mental health
- You must be willing to use contraception for 3 months after taking the study drug if you can become pregnant or father a child
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests how a new experimental medication (HSK55879) is tolerated and processed by the body in healthy volunteers. Researchers will also check how food affects the drug's absorption to help determine safe dosing for future patient studies.
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new medicine, HRS-8364, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
This trial tests a new drug called HRS-6213. It is first given to healthy volunteers to check safety, and then to patients with solid tumors to see if it can help treat their cancer.
Hear when a new Malignant Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.